Table 1

Baseline characteristics of patients in SWEFOT study treated with methotrexate in monotherapy

Overall (n=405)In model* (n=322)
Women, n (%)318 (71%)228 (71%)
Age (years), median (IQR)57 (44–64)57 (44–63)
Cigarette smoking status
 Current smokers, n (%)87 (25%)82 (25%)
 Past smokers, n (%)140 (39%)126 (39%)
 Never smokers, n (%)127 (36%)114 (36%)
Symptom duration (months), median (IQR)6 (4–8)6 (4–9)
Rheumatoid factor positive, n (%)175 (49%)145 (51%)
Anti-CCP antibody positive, n (%)246 (64%)205 (64%)
Concurrent prednisolone, n (%)55 (14%)38 (12%)
Concurrent NSAIDs, n (%)248 (61%)206 (64%)
HAQ score, median (IQR)1.1 (0.8–1.5)1.1 (0.8–1.6)
DAS28, median (IQR)5.7 (4.9–6.3)5.7 (5.0–6.4)
SDAI, median (IQR)32.9 (25.1–41.8)32.9 (25.1–42.7)
CDAI, median (IQR)29.6 (23.2–38.0)29.6 (23.0–38.7)
  • anti-CCP, anti-cyclic citrullinated peptide antibody; CDAI, Clinical Disease Activity Index; HAQ, Health Assessment Questionnaire; NSAID, non-steroidal anti-inflammatory drug; SDAI, Simple Disease Activity Index.